ABSTRACT BACKGROUND Longstanding persistent (LSP) atrial fibrillation (AF) is the most challenging type of AF. In addition to
Importantly, many non-PV areas may be the source of initiation and maintenance of AF (12) (13) (14) (15) (16) (17) (18) (19) (20) . The most common sites are the superior vena cava (SVC), the ligament of Marshall, the coronary sinus (CS), the crista terminalis, and the left atrial (LA) posterior wall (21) . Furthermore, the LA appendage (LAA) was described as an underreported site of AF initiation in a nonrandomized prospective study (12) . Tilz et al. (5) reported a very poor outcome at long-term follow-up in patients undergoing ablation for LSPAF.
In their study, the LAA was not a target for ablation (5) . block size of 4. The study administrator at the enrolling site was provided with blocks of randomization numbers and was required to store them at a restricted-access location. The trial arm allocation was provided to the investigator when the patient was ready for randomization. All patients signed an informed written consent to the procedure. The study was approved by the Institutional Review Boards of the participating institutions.
METHODS

BELIEF (Effect of
The study was designed to detect at least a 20% difference in success rates (50% to 70%) at 12-month follow-up (hazard ratio [HR]: 0.515; null hazard: 0.058) at 2-sided type I error of 0.05 and 80% power.
Briefly, 2 right groin femoral accesses (8-F sheath) were used to perform a double transseptal catheterization. A 20-mm decapolar circular mapping catheter was used for mapping the left atrium (Lasso, Biosense
Webster, Baldwin Park, California), and a 3.5-mm open irrigated-tip ablation catheter was used for ablation (12, 21 ).
An 11-F left femoral venous access was used to guide a 10-F phased-array ultrasound imaging catheter (Biosense Webster) in the right atrium (12, 21) . The right internal jugular vein was accessed and was used to place a 20-pole catheter; the distal poles were positioned in the CS, and the proximal poles were placed along the crista terminalis. All procedures were performed with uninterrupted oral anticoagulation strategies with warfarin and/or novel oral anticoagulant agents as described elsewhere by our group (22) (23) (24) (25) (26) (27) (28) (29) .
Before transseptal access, all patients received a heparin bolus, and extra heparin boluses were administered to maintain the activated clotting time higher than 350 s (29) . AADs were discontinued 3 to 5 days before ablation, whereas amiodarone was discontinued 4 to 6 months before the procedure (30). The study enrolled 173 patients with longstanding persistent atrial fibrillation (AF) and randomly assigned them to undergo empirical left atrial appendage (LAA) electrical isolation plus standard ablation (group 1) or standard ablation alone (group 2).
Di Biase et al. After isoproterenol challenge and non-PV trigger ablation, the SVC was empirically isolated in all As for the ablation, the steps were the same in groups 1 and 2, with the exception of the LAA.
In group 1, LAA electrical isolation was performed empirically (EEI-LAA) before the isoproterenol test and after the isolation of the PV antrum extended to the entire posterior wall, down to the CS, and to the left side of the septum. The electrical isolation was performed in AF or immediately after direct current cardioversion in sinus rhythm. EEI-LAA has been extensively described elsewhere (12, 21) . In all patients, after verification and reisolation of previously ablated areas, empirical electrical left atrial appendage isolation as described earlier was performed in all patients.
POST-ABLATION MANAGEMENT AND FOLLOW-UP.
All patients were discharged on warfarin with a target international normalized ratio (INR) of 2 to 3 or on novel oral anticoagulant agents on the basis of preablation oral anticoagulation management or their previously ineffective AADs, except for amiodarone.
Oral anticoagulation was continued for a minimum of 6 months after the blanking period, whereas AADs were administered only during the blanking period. Once
AADs were discontinued, any recurrences were reported off AADs. All patients were followed up until the study's end. All enrolled patients who underwent the index procedure constituted the intent-to-treat population and were the subject for safety and efficacy analyses.
All tests were 2-sided, and a value of p < 0.05 was considered statistically significant. Analyses were performed using SAS version 9.2 (SAS Institute, Inc.).
RESULTS
A total of 173 patients were enrolled in the study.
Baseline and major clinical characteristics were not different between the groups ( Table 1) . Groups 1 and 2 had comparable procedural and fluoroscopy times. However, the mean RF time was approximately 16 min shorter in group 2 (p < 0.001) Values are n (%) or %. *This was the documented firing from the superior vena cava including premature atrial complexes, but the superior vena cava was empirically isolated in both groups unless phrenic nerve capture at the ablation site was detected. †The 36% reflects sustained and nonsustained arrhythmia firing including premature atrial complexes. By study design, the left atrial appendage was ablated in this group only in case of firing leading to sustained atrial fibrillation or tachycardia, which happened in 8 (9%) patients.
NA ¼ not applicable; PV ¼ pulmonary vein. 
DISCUSSION
This randomized study showed that empirical isolation of the LAA improved freedom from AF/AT in patients with LSPAF (Central Illustration). AADs ¼ antiarrhythmic drugs; other abbreviation as in Figure 1 . Figures 1 and 3 .
LAA Electrical Isolation in Longstanding Persistent Atrial Fibrillation
Importantly, evidence of LAA firing was present in only 8% of patients undergoing the standard approach, a finding suggesting the relevance of empirical isolation of the LAA to achieve long-term freedom from atrial arrhythmias.
A major drawback could be represented by the need for long-term anticoagulation, given that the lack of proper mechanical function in the LAA may contribute to stroke. However, it is important to consider that most patients included in this trial would have been receiving long-term oral anticoagulation irrespective of their ablation because of their CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, female sex category) score. Furthermore, considering the high success rate after 2 procedures, the risk of long-term anticoagulation is a worthwhile price to pay to stay in sinus rhythm. Besides, several LAA closure devices are available that could be an alternative to long-term anticoagulation for these patients.
This study reinforced the concepts that in patients with LSPAF, PV isolation alone is insufficient to achieve satisfactory results (5). In group 2, in which in addition to PV isolation, only non-PV triggers disclosed by isoproterenol challenge were ablated, the success rate was 28% at 12-month follow up, and that rate increased to 56% after an average of 1.3 procedures once EEI-LAA was added. In the group that had, in addition to PV isolation and non-PV trigger ablation, empirical isolation of the LAA, the success rate was 56% after a single procedure, and it increased to 76% following an average of 1.3 procedures.
The relevance of EEI-LAA in treating these patients is of utmost importance. In contrast to the paper by shown wide variability in assessing configuration, shape, and dimension (34, 35) . In approximately 50%
of the population, the LAA is composed of 2 lobes, and in one-third of the population, it has 3 lobes (36) (37) (38) . Because the LAA has a very thin wall and may be prone to perforation, the operator should be cautious when trying to achieve EEI-LAA.
Although it is fair to say that expert operators were involved in this trial, no major complications were 
